Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

(2020) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans

(2020) Xiling Jiang et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

T cell-engaging therapies — BiTEs and beyond

(2020) Maria-Elisabeth Goebeler et al.   Nature Reviews Clinical Oncology

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

(2020) Chiara Caraccio et al.   Frontiers in Immunology

A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor

(2020) Huilin Ma et al.   AAPS Journal

Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

(2020) Iraj Hosseini et al.   npj Systems Biology and Applications

Measurement and Quantitative Characterization of Whole-Body Pharmacokinetics of Exogenously Administered T Cells in Mice

(2019) Antari Khot et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances

(2019) Lin Yu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

(2019) Kirsten L. Moek et al.   CLINICAL CANCER RESEARCH

A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®

(2019) Alison Betts et al.   AAPS Journal

Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics

(2019) Zhe Li et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

A review of bispecific antibodies and antibody constructs in oncology and clinical challenges

(2019) Frans V. Suurs et al.   PHARMACOLOGY & THERAPEUTICS

Effect of Size on Solid Tumor Disposition of Protein Therapeutics

(2019) Zhe Li et al.   DRUG METABOLISM AND DISPOSITION

Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma

(2019) Siler H. Panowski et al.   MOLECULAR CANCER THERAPEUTICS

Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

(2018) Olivia Campagne et al.   CLINICAL CANCER RESEARCH

Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells

(2018) Kevin M. Friedman et al.   HUMAN GENE THERAPY

Next generation of immune checkpoint therapy in cancer: new developments and challenges

(2018) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents

(2018) Xiling Jiang et al.   mAbs

Relative Target Affinities of T-Cell–Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model

(2018) Danielle Mandikian et al.   MOLECULAR CANCER THERAPEUTICS

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Bispecific antibodies: design, therapy, perspectives

(2018) Sergey Sedykh et al.   Drug Design Development and Therapy

Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety

(2018) Diego Ellerman   METHODS

An extended mathematical model of tumor growth and its interaction with the immune system, to be used for developing an optimized immunotherapy treatment protocol

(2017) Milad Qomlaqi et al.   MATHEMATICAL BIOSCIENCES

Influence of Molecular size on the clearance of antibody fragments

(2017) Zhe Li et al.   PHARMACEUTICAL RESEARCH

Oncolytic Viruses in Cancer Treatment

(2017) Sean E. Lawler et al.   JAMA Oncology

Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling

(2016) Abhinav Tiwari et al.   AAPS Journal

Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications

(2016) Min Zhu et al.   CLINICAL PHARMACOKINETICS

Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: An Integrated PK/PD Modeling Approach

(2016) X Chen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

(2016) Michael Ghermezi et al.   HAEMATOLOGICA

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

(2016) S Hipp et al.   LEUKEMIA

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients

(2016) Michael Ghermezi et al.   HAEMATOLOGICA

A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins

(2015) Katherine L. Gill et al.   AAPS Journal

Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory

(2015) Armin Sepp et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Splenic Lymphoid Subsets With Less Well-Recognized Phenotypes Mimic Aberrant Antigen Expression

(2013) Nidhi Aggarwal et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

The Antibody Drug Absorption Following Subcutaneous or Intramuscular Administration and Its Mathematical Description by Coupling Physiologically Based Absorption Process with the Conventional Compartment Pharmacokinetic Model

(2013) Liang Zhao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Bone marrow and the control of immunity

(2011) Ende Zhao et al.   Cellular & Molecular Immunology

Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human

(2011) Dhaval K. Shah et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

In vivo biodistribution and accumulation of 89Zr in mice

(2011) Diane S. Abou et al.   NUCLEAR MEDICINE AND BIOLOGY